iCell Gene Therapeutics
- Biotech or pharma, therapeutic R&D
iCell Gene Therapeutics is a private, clinical-stage biopharmaceutical company with a robust pipeline of first-in-class cellular therapies for autoimmune diseases and cancer.
Our lead program, ICG 318 is a BCMA-CD19-IL-15/ IL-15Rα sushi compound CART cell therapy being investigated in Systemic Lupus Erythematosus. IIT data presented and published in 2024 demonstrated complete immune reset and remission with all elevated autoantibodies eliminated and no relapse at a median follow up of over 470 days. We are currently initiating a Phase I/ II US clinical trial with ICG 318 in SLE.
Commercial rights to ICG 318 have been out licensed in China. We are currently exploring additional out-licensing opportunities.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}